Immuneering (IMRX) Liabilities and Shareholders Equity (2020 - 2026)

Immuneering's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $214.8 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 323.84% year-over-year to $214.8 million in Q1 2026; TTM through Mar 2026 was $727.9 million, a 192.29% increase from a year earlier, with the FY2025 full-year figure at $232.0 million, up 340.08% from the prior year.
• Liabilities and Shareholders Equity eased to $214.8 million in Q1 2026 per IMRX's latest filing, from $232.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $241.1 million in Q3 2025 and bottomed at $40.1 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $113.9 million (2023), against an average of $121.4 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 48.61% in 2024 and soared 340.08% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $122.4 million in 2022, then fell by 16.17% to $102.6 million in 2023, then plunged by 48.61% to $52.7 million in 2024, then surged by 340.08% to $232.0 million in 2025, then decreased by 7.4% to $214.8 million in 2026.
• Per Business Quant, the three latest IMRX Liabilities and Shareholders Equity figures stand at $214.8 million (Q1 2026), $232.0 million (Q4 2025), and $241.1 million (Q3 2025).